Tyrosine Protein Phosphatase Non Receptor Type 1 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)- Pipeline Review, H2 2019’, provides in depth analysis on Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders and Oncology under development targeting Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)

– The report reviews Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“DepYmed Inc

Kaneq Bioscience Ltd

OliPass Corporation

Preveceutical Medical Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Overview

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Companies Involved in Therapeutics Development

DepYmed Inc

Kaneq Bioscience Ltd

OliPass Corp

Preveceutical Medical Inc

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Drug Profiles

Antisense Oligonucleotide to Inhibit PTP1B for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPT-157633 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPM-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KQ-791 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-009629 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PTPB1 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PTP1B for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PTP1B for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PTP1B for Type 2 Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trodusquemine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Dormant Products

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Discontinued Products

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC

3.1.3.48) - Product Development Milestones

Featured News & Press Releases

Jun 27, 2018: Progress toward improved Wilson's disease drug

May 27, 2014: DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer

Jul 10, 2013: Local foundation raises $15,000 for breast cancer research at Cold Spring Harbor Laboratory

Sep 29, 2011: Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity

Feb 10, 2009: Genaera Presents Preliminary Phase 1b Data For Trodusquemine (MSI-1436)

Jan 22, 2009: Genaera Presents Promising Preclinical Data For Trodusquemine (MSI-1436) At Keystone Symposia

Dec 01, 2008: Genaera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics

Oct 06, 2008: Genaera Corporation Reports Phase 1 Data For Trodusquemine (MSI-1436) At The North American Association For The Study Of Obesity Annual Meeting

Jul 25, 2008: Genaera Releases Phase 1 Data And New Preclinical Data On The CNS Function Of Trodusquemine (MSI-1436) At CBI Obesity Summit

Jul 14, 2008: Genaera Corporation Presents Data On Mechanism Of Inhibition Of PTP-1B For Trodusquemine (MSI-1436) At Federation Of American Societies For Experimental Biology (FASEB) Meeting

Jun 09, 2008: Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association

Mar 28, 2008: Genaera Corporation Announces MSI-1436 Data Presented At Society Of Neuroscience Meeting

Jan 24, 2008: Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At Keystone Symposia

Oct 23, 2007: Genaera Corporation Presents Phase 1 Data For Trodusquemine (MSI-1436) At The North American Association For The Study Of Obesity Annual Meeting

Oct 23, 2007: Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data At The North American Association For The Study Of Obesity Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by DepYmed Inc, H2 2019

Pipeline by Kaneq Bioscience Ltd, H2 2019

Pipeline by OliPass Corporation, H2 2019

Pipeline by Preveceutical Medical Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports